Drugs / QL-007
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03770624 | Oct 2018 → Mar 2019 | chronic hepatitis B virus infection | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03244085 | Aug 2017 → Oct 2018 | chronic hepatitis B virus infection | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04157257 | Jul 2019 → Dec 2020 | chronic hepatitis B virus infection | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04157699 | Jul 2019 → Dec 2020 | chronic hepatitis B virus infection | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04157699 ↗ |
| Route | Oral | “QL 007 will be administered orally daily over the 28 days under fasted state.” NCT03244085 ↗ |